Characteristics and prognosis of patients with non-immunoglobulin-M monoclonal gammopathy of undetermined significance: a retrospective study.
Female
Immunoparesis
Monoclonal gammopathy of undetermined significance
Multiple myeloma
Non-IgM monoclonal gammopathy
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
18
07
2018
accepted:
30
10
2018
revised:
24
10
2018
pubmed:
9
11
2018
medline:
7
3
2019
entrez:
9
11
2018
Statut:
ppublish
Résumé
Non-immunoglobulin (Ig)-M monoclonal gammopathy of undetermined significance (MGUS) is a precursor lesion with the potential to evolve into a malignant plasma cell neoplasm. The prevalence of MGUS differs by ethnicity and is lower in the Japanese population than in the Western population. However, there is limited evidence about the clinical course of MGUS in Asian races. The present study aims at elucidating the clinical course and prognosis of Japanese patients with non-IgM MGUS in the clinical setting. We retrospectively examined 1009 patients with non-IgM MGUS identified by screening procedures. The median overall survival of these patients was > 20 years, and only one-fifth patients died of plasma cell neoplasms. The cumulative incidence of plasma cell neoplasms requiring treatment was 19%. Multivariate analysis revealed that immunoparesis and female gender were independent factors affecting treatment requirement. Although the characteristics and clinical course of patients with non-IgM MGUS obtained in this study were found to be essentially similar to those of previous studies, we report here for the first time that female gender is a significant independent factor for requiring treatment.
Identifiants
pubmed: 30406907
doi: 10.1007/s12185-018-2555-7
pii: 10.1007/s12185-018-2555-7
doi:
Substances chimiques
Immunoglobulin M
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
154-161Références
N Engl J Med. 2002 Feb 21;346(8):564-9
pubmed: 11856795
Blood. 2005 Aug 1;106(3):812-7
pubmed: 15855274
Blood. 2006 Feb 1;107(3):904-6
pubmed: 16210333
Blood. 2007 Oct 1;110(7):2586-92
pubmed: 17576818
Mayo Clin Proc. 2007 Dec;82(12):1474-9
pubmed: 18053454
J Clin Oncol. 2010 Mar 20;28(9):1606-10
pubmed: 20177023
Blood. 2010 Oct 14;116(15):2651-5
pubmed: 20610813
N Engl J Med. 2011 Aug 4;365(5):474-5
pubmed: 21812699
Leukemia. 2013 Apr;27(4):941-6
pubmed: 23183428
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
N Engl J Med. 2013 Aug 1;369(5):438-47
pubmed: 23902483
Blood. 2014 Jan 16;123(3):338-45
pubmed: 24222331
Lancet Oncol. 2014 Nov;15(12):e538-48
pubmed: 25439696
Blood Cancer J. 2015 Aug 28;5:e345
pubmed: 26314987
Int J Hematol. 2016 Sep;104(3):271-2
pubmed: 27283410
J Clin Exp Hematop. 2017;57(2):47-53
pubmed: 29021514
Blood Adv. 2017 Dec 21;1(27):2790-2798
pubmed: 29296931
Clin Biochem. 1982 Feb;15(1):17-21
pubmed: 7067072